"versionIdentifier","id","instanceType","rationale","uuid:ID"
"2","StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","65d55bf0-b738-4767-a656-0d376f031770"
